Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
SXTPW
SXTPW
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SXTPW News
60 Degrees Pharmaceuticals Reveals Name of Clinical Trial for Chronic Babesiosis: B-FREE Study
Oct 09 2025
Newsfilter
60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion
Jul 15 2025
Newsfilter
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
Jun 04 2025
Newsfilter
Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21
Apr 10 2025
Newsfilter
Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
Apr 08 2025
Newsfilter
60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Feb 06 2025
Newsfilter
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
Dec 23 2024
Newsfilter
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital
Dec 11 2024
Newsfilter
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
Nov 14 2024
Newsfilter
60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Sep 06 2024
Newsfilter
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
Aug 28 2024
Newsfilter
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
Aug 14 2024
Newsfilter
60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
Aug 12 2024
Newsfilter
60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
Aug 12 2024
Newsfilter
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
Aug 06 2024
Newsfilter
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
Aug 06 2024
Newsfilter
Show More News
